Company: SCLXW
Filing Date: 2025-01-17
Form Type: 10-Q
Source: 0000950170-25-006755
Chunk: 98

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 10-Q
Item: Item 1
Chunk 98
---
 an aggregate of 8,500,000 shares of Common Stock are not vested as of the closing date of September 21, 2023 and the vesting is based on the passage of time, the Company’s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). Therefore, these Subsequent Penny Warrants are included in the computation for diluted net income per share once all other exercise contingencies are removed except for the passage of time. 

 34

The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: 

        September 30,

        December 31,

        2024

        2023

        Stock options

        34,361,475

        33,123,798

        Public Warrants

        5,467,692

        6,854,309

        Firm Warrants

        5,568,153

        —

        RDO Common Warrants

        15,000,000

        —

        Placement Agent Warrants

        1,200,000

        —

        Deposit Warrant

        3,250,000

        —

        Fee Warrant

        250,000

        —

        Retainer Shares

        14,000,000

        4,000,000

        Private Warrants

        1,000,000

        3,613,383

        Representative Warrants

        470,588

        —

        Shares issuable pursuant to ESPP

        183,546

        29,806

        Shares issuable under Sponsor Interest Purchase Agreement

        300,000

        —

        Convertible Debentures

        —

        546,921

        Total

        81,051,454

        48,168,217

13. Subsequent Events Issuance of Tranche B Notes On October 7, 2024, the Company entered into a securities purchase agreement (the “Tranche B Securities Purchase Agreement”) with certain institutional investors (collectively, “Investor”) and Oramed (together with the Investor, the “Tranche B Noteholders”), to refinance a portion of the Oramed Note and pay off certain other indebtedness of the Company. Pursuant to the Tranche B Securities Purchase Agreement, the Company